Axovia Therapeutics is deeply grateful to A Race Against Blindness for its additional $1.1 million grant, which closes the remaining funding gap and enables initiation of the AXIS (AXV-101) clinical trial for children living with Bardet-Biedl Syndrome 1 in the coming months. With this support, Axovia remains firmly committed to moving AXIS into the clinic as quickly and responsibly as possible, advancing this first-in-human study to evaluate whether AXV-101 can safely address the underlying cause of BBS1-related vision loss.
